The AF market offers opportunities driven by new pipeline drugs such as FXI/FXIa inhibitors addressing bleeding concerns and growing prevalence of treated AF cases. However, growth is challenged by ...

Meta Platforms (META) delivered EPS growth of 5.4% most recently, below its robust 17.2% five-year average, while net profit margins tightened to 30.9% from last year’s 35.6%. The share price sits at ...